Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees

Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees

Background: Latent Tuberculosis infection (LTBI) has a large global burden especially among refugees. We aimed to test the cost effectiveness of weekly rifapentine plus isoniazid for 3 months (3HP) versus nine months of daily isoniazid (INH-9) to treat LTBI in Syrian refugees residing in Turkey. Met...

Full description

Bibliographic Details
Main Authors:	Ghassan Ilaiwy, David W. Dowdy
Format:	Article
Language:	English
Published:	Elsevier 2021-08-01
Series:	Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Subjects:	Tuberculosis Preventive therapy Resource allocation HIV
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405579421000516

Similar Items

Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
by: Wendy A. Lai, et al.
Published: (2022-12-01)

Pharmacokinetics of isoniazid and rifapentine in young pediatric patients with latent tuberculosis infection
by: Weeraya Phaisal, et al.
Published: (2022-09-01)

Pharmacoprophylactic equivalence of rifapentine compared with isoniazid: an appraisal for HIV-infected population
by: Beuy Joob, et al.
Published: (2021-01-01)

Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial
by: Nyanda Elias Ntinginya, et al.
Published: (2022-06-01)

Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events
by: Shang-Yi Lin, et al.
Published: (2019-02-01)

Short-course isoniazid plus rifapentine therapy for latent tuberculosis in Brazil
by: Julio Croda
Published: (2015-10-01)

Efficacy of Short-course Weekly Isoniazid and Rifapentine Regimen as Tuberculosis Preventive Treatment among Population at Risk of Developing Disease: A Systematic Review and Meta-analysis
by: Ilangovan Ilavarasan, et al.
Published: (2024-02-01)

Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis
by: I Frésard, et al.
Published: (2011-08-01)

Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses
by: Christopher Pease, et al.
Published: (2017-04-01)

Safety and Tolerability of Six Months of Isoniazid Plus Pyridoxine or Three Months of Rifampicin for Tuberculosis among Subjects with Diabetes Mellitus: A Randomized Trial
by: Karla M. Tamez-Torres, et al.
Published: (2023-07-01)

Timing of treatment interruption among latently infected tuberculosis cases treated with a nine-month course of daily isoniazid: findings from a time to event analysis
by: Marie Nancy Séraphin, et al.
Published: (2019-09-01)

Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda—patient and health worker perspectives
by: Fred C. Semitala, et al.
Published: (2021-06-01)

Rifapentine for latent tuberculosis infection treatment in the general population and human immunodeficiency virus-positive patients: summary of evidence
by: Júlia Souza Vidal, et al.
Published: (2015-10-01)

Comparative analysis of the effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS treated with isoniazid
by: Konrad Juszkiewicz, et al.
Published: (2019-09-01)

Isoniazid Preventive Therapy Uptake and Its Effect on Tuberculosis Incidence Among People Living with HIV in Illubabor and Buno Bedelle Zones, South-West Ethiopia, 2022: A Retrospective Cohort Study
by: Mulatu G, et al.
Published: (2023-11-01)

A study on comparative efficacy of anti tubercular chemoprophylaxis with 2 different regimens: 2 months of rifampicin and pyrazinamide and 6 months of daily isoniazid and rifampicin in HIV infected tuberculin reactors
by: Prasad BNBM
Published: (2006-01-01)

Strengthening management of latent tuberculosis infection and accelerating the elimination of the tuberculosis epidemic
by: SHEN Xin, et al.
Published: (2023-03-01)

Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs
by: Riti Sharan, et al.
Published: (2022-09-01)

Pyrosequencing for rapid detection of tuberculosis resistance to Rifampicin and Isoniazid in Syrian and Lebanese clinical isolates
by: M Hamze, et al.
Published: (2015-01-01)

Latent Tuberculosis Treatment among Hard-to-Reach Ethiopian Immigrants: Nurse-Managed Directly Observed versus Self-Administered Isoniazid Therapy
by: Hashem Bishara, et al.
Published: (2023-02-01)

High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection-A single center study.
by: Heng Yang, et al.
Published: (2021-01-01)

Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness.
by: Nwabunie Nwana, et al.
Published: (2019-01-01)

Uptake and Completion of Tuberculosis Preventive Treatment Using 12-Dose, Weekly Isoniazid–Rifapentine Regimen in Bangladesh: A Community-Based Implementation Study
by: Md. Toufiq Rahman, et al.
Published: (2023-12-01)

Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study
by: Grace A. Shayo, et al.
Published: (2017-07-01)

Response to: Socio-political prescriptions for latent tuberculosis infection are required to prevent reactivation of tuberculosis
by: Greg J. Fox, et al.
Published: (2017-05-01)

Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: Is anti-HCV a risk factor?
by: Lysandro Alsina Nader, et al.
Published: (2010-01-01)

Isoniazid, The Frontline of Resistance in Mycobacterium tuberculosis
by: James B. Whitney, et al.
Published: (2002-12-01)

Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania
by: Renatus Fabiano Nyarubamba, et al.
Published: (2022-11-01)

Different diets and their effect on tuberculosis prevention in HIV patients
by: Hamidreza Kouhpayeh
Published: (2022-01-01)

ISONIAZID - MONORESISTANT TUBERCULOSIS IN BULGARIA
by: Stanislava Yordanova, et al.
Published: (2020-05-01)

Knowledge, attitudes and practices of doctors regarding isoniazid preventive therapy in HIV/AIDS patients at Odi District Hospital, Gauteng province, South Africa
by: A. T. Abdulrazaak, et al.
Published: (2018-12-01)

Mortality in the first six months among HIV-positive and HIV-negative patients empirically treated for tuberculosis
by: Helena Huerga, et al.
Published: (2019-02-01)

Prevalence of latent Mycobacterium tuberculosis infection in prisoners
by: Pedro Daibert de Navarro, et al.

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
by: Ian M Rosenthal, et al.
Published: (2007-12-01)

Tuberculosis contact-tracing among Syrian refugee populations: lessons from Jordan
by: Edouard Hosten, et al.
Published: (2018-07-01)

Inequality in uptake of isoniazid prevention therapy and Mantoux test among pregnant women with HIV in the Eastern Cape, South Africa
by: Oladele Vincent Adeniyi, et al.
Published: (2019-10-01)

Low level of tuberculosis preventive therapy incompletion among people living with Human Immunodeficiency Virus in eastern Uganda: A retrospective data review
by: Paul Lwevola, et al.
Published: (2021-12-01)

Protocol for a Case-Control Study to Investigate the Association of Pellagra With Isoniazid Exposure During Tuberculosis Preventive Treatment Scale-Up in Malawi
by: Scott A. Nabity, et al.
Published: (2020-11-01)

Gaps in the care cascade for screening and treatment of refugees with tuberculosis infection in Middle Tennessee: a retrospective cohort study
by: Adoma Manful, et al.
Published: (2020-08-01)

Factors associated with isoniazid preventive treatment interruption and completion among PLHIV in Gombe Hospital, Uganda, 2017–2019
by: Emmanuel Ssendikwanawa, et al.
Published: (2023-05-01)